Apixaban is a direct inhibitor of factor Xa, and is a potential alternative for the treatment of acute venous thromboembolism.
These results suggest a lack of clear superiority of apixaban relative to enoxaparin.
Apixaban is an oral alternative with similar efficacy and safety to existing anticoagulant therapies.
